MIR205HG and prostate adenocarcinoma: TCGA data show LEADR/MIR205HG upregulation in tumors with basal phenotype (e.g., cervical and lung squamous cell cancers) and downregulation in breast and prostate adenocarcinomas compared to their normal counterparts, thus mirroring miR-205 modulations (Fig. 1b; Supplementary Fig. 2a).